Atopic dermatitis and role of Relizema: a multi-country user experience


  • Cheong W. Kwong Specialist Skin Clinic and Associates Private Limited, Singapore
  • Giovanni Pellacani University of Rome, La Sapienza, Italy
  • Supenya Varothai Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Thailand
  • Ma L. Palmero Department of Dermatology, The Medical City, Philippines
  • Srie Prihianti Department of Pediatric Dermatology, Padjadjaran University, Bandung, Indonesia
  • Frances Tan Marikina Valley Medical Center and Victor R. Potenciano Medical Center, Philippines
  • Leong K. Fon Department of Pediatric Dermatology, General Hospital Kuala Lumpur, Malaysia
  • Ho K. Keung Department of Dermatology, Grandpire Medical Clinic, Hong Kong
  • Chan Yung Department of Dermatology, Grandpire Medical Clinic, Hong Kong
  • Zakiudin Munasir A.Menarini Asia Pacific, China
  • Lisa Braganza Specialist Skin Clinic and Associates Private Limited, Singapore



Atopic dermatitis, Relizema™ cream, Prescription emollient device


Atopic dermatitis (AD) is characterized by itching or pruritus, erythematous lesions, pruritus, and a skin barrier defect. Repeated scratching can trigger the itch-scratch cycle. Itching is associated with an adverse impact on quality of life. The first-line treatment of AD includes the use of topical corticosteroids for atopic dermatitis. However, parents of children with atopic dermatitis are often reluctant to accept the use of topical corticosteroids due to their concern of adverse effects flare-up. Relizema™ cream is a prescription emollient device (PED) multi-ingredients moisturizer formulation that has been indicated for the treatment of signs and symptoms of dermatitis. It is approved as medical device (MD) class IIa in Europe and it is registered as a topical medical device in countries of Asia Pacific. A consensus meeting of 9 dermatologists from multiple countries in Asia Pacific region treating atopic dermatitis was conducted. The dermatologists presented their cases of atopic dermatitis. PED was reported by patients to offer good relief of symptoms and improve skin softness unlike other moisturizers. In fact, a few patients reported relief with Relizema™ cream after using other moisturizers which were not demonstrating clinical effectiveness. Patients reported they noticed a softness in their skin after the application of the PED. PED was effective even in patients with lichenified skin. The formulation which is enriched with antioxidants helped relieve eczema. Due to its steroid-free formulation, the PED can be continued as a part of long-term maintenance treatment to maintain healthy skin conditions, prolong remission, and prevent recurrence.


Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest. 2006;116(5):1150-8.

Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician. 2020;101(10):590-8.

Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51.

Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82-91.

Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-31.

Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139(5):834-9.

Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol. 2005;52(4):579-82.

Wen HJ, Chen PC, Chiang TL, Lin SJ, Chuang YL, Guo YL. Predicting risk for early infantile atopic dermatitis by hereditary and environmental factors. Br J Dermatol. 2009;161(5):1166-72.

Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8):115-23.

Ruiz RG, Kemeny DM, Price JF. Higher risk of infantile atopic dermatitis from maternal atopy than from paternal atopy. Clin Exp Allergy. 1992;22(8):762-6.

Ghamrawi R, Bell KA, Balogh EA, Strowd LC, Feldman SR. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020;20(12):1435-45.

Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol. 2009;160(3):642-4.

Schmitt J, Csötönyi F, Bauer A, Meurer M. Determinants of treatment goals and satisfaction of patients with atopic eczema. J Dtsch Dermatol Ges. 2008;6(6):458-65.

Langenbruch A, Radtke M, Franzke N, Ring J, Foelster-Holst R, Augustin M. Quality of health care of atopic eczema in Germany: results of the national health care study Atopic Health. J Eur Acad Dermatol Venereol. 2014;28(6):719-26.

Wittkowski A, Richards HL, Griffiths CE, Main CJ. Illness perception in individuals with atopic dermatitis. Psychol Health Med. 2007;12(4):433-44.

Camfferman D, Kennedy JD, Gold M, Martin AJ, Winwood P, Lushington K. Eczema, sleep, and behavior in children. J Clin Sleep Med. 2010;6(6):581-8.

Arnold RJ, Donnelly A, Altieri L, Wong KS, Sung J. Assessment of outcomes and parental effect on Quality-of-Life endpoints in the management of atopic dermatitis. Manag Care Interface. 2007;20(2):18-23.

Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192-9.

Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984-92.

Silverberg JI. Association between childhood eczema and headaches: an analysis of 19 US population-based studies. J Allergy Clin Immunol. 2016;137(2):492-9.

Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol. 2015;151(4):401-9.

Magin P. Appearance-related bullying and skin disorders. Clin Dermatol. 2013;31(1):66-71.

Zuberbier T, Orlow SJ, Paller AS. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-32.

Silverberg NB, Silverberg JI. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. 2015;96(6):359-61.

Strathie Page S, Weston S, Loh R. Atopic dermatitis in children. Aust Fam Physician. 2016;45(5):293-6.

Relizema Product monograph. Available at: Accessed on 14 February 2022.

Hebert AA. Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis. Int J Women's Dermatol. 2020;6(4):331-3.

Hebert AA, Pellacani G, Micali G. Advancing Breakthrough Innovative Treatment in Paediatric Dermatitis and Various Skin Disorders. EMJ Dermatol. 2021;9(4):2-9.




How to Cite

Kwong, C. W., Pellacani, G., Varothai, S., L. Palmero, M., Prihianti, S., Tan, F., K. Fon, L., K. Keung, H., Yung, C., Munasir, Z., & Braganza, L. (2022). Atopic dermatitis and role of Relizema: a multi-country user experience. International Journal of Research in Medical Sciences, 10(8), 1747–1754.



Case Series